| 1.96 -0.08 (-3.92%) | 07-13 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 2.48 | 1-year : | 2.89 |
| Resists | First : | 2.12 | Second : | 2.48 |
| Pivot price | 1.95  |
|||
| Supports | First : | 1.8 | Second : | 1.6 |
| MAs | MA(5) : | 2.03 |
MA(20) : | 1.89 |
| MA(100) : | 1.82 |
MA(250) : | 1.72 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 70.9 |
D(3) : | 79.7 |
| RSI | RSI(14): 56.6 |
|||
| 52-week | High : | 2.25 | Low : | 1.33 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ IKT ] has closed below upper band by 49.8%. Bollinger Bands are 24% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.05 - 2.06 | 2.06 - 2.07 |
| Low: | 1.92 - 1.93 | 1.93 - 1.94 |
| Close: | 1.94 - 1.96 | 1.96 - 1.97 |
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to improve areas of the molecule that might play a role in the gastrointestinal side effects associated with imatinib, while maintaining systemic exposure and efficacy through oral administration. The company has completed non-human primate safety studies and a bioequivalence clinical study in healthy volunteers, establishing dose equivalence with imatinib. IKT-001 is currently being evaluated in a global, adaptive Phase 3 clinical trial (IMPROVE-PAH), with endpoints including pulmonary vascular resistance and 6-minute walk distance. Inhibikase Therapeutics, Inc. entered into a collaborative research and development agreement with Sphaera Pharma Pte. Ltd., which was subsequently assigned to Pivot Holding LLC, for prodrug technology development and maintains an exclusive license for IKT-001. The company was founded in 2008 and is headquartered in Wilmington, Delaware.
Tue, 14 Jul 2026
Inhibikase Therapeutics Sells $50M of Stock to RA Capital via ATM Facility - TradingView
Tue, 14 Jul 2026
Inhibikase Therapeutics (NASDAQ:IKT) Rating Increased to Strong-Buy at LADENBURG THALM/SH SH - MarketBeat
Tue, 14 Jul 2026
Inhibikase Therapeutics (Nasdaq: IKT) sells 25M shares for $50M cash - Stock Titan
Tue, 14 Jul 2026
Inhibikase's $50M share sale could support Phase 3 PAH readout - Stock Titan
Tue, 14 Jul 2026
Inhibikase Therapeutics Announces Sale of $50 Million of Shares Through its At-the-Market (ATM) Facility - GlobeNewswire
Tue, 14 Jul 2026
Inhibikase Therapeutics (NASDAQ:IKT) Shares Down 3.9% - Here's What Happened - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Pharmaceuticals
|
|
| Shares Out | 132 (M) |
| Shares Float | 87 (M) |
| Held by Insiders | 6.4 (%) |
| Held by Institutions | 93.4 (%) |
| Shares Short | 19,420 (K) |
| Shares Short P.Month | 18,510 (K) |
| EPS | -0.44 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.98 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -22.7 % |
| Return on Equity (ttm) | -40.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.37 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -36 (M) |
| Levered Free Cash Flow | -15 (M) |
| PE Ratio | -4.46 |
| PEG Ratio | 0 |
| Price to Book value | 2 |
| Price to Sales | 0 |
| Price to Cash Flow | -7.25 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|